scispace - formally typeset
Open AccessJournal ArticleDOI

Myeloid-derived miR-223 regulates intestinal inflammation via repression of the NLRP3 inflammasome

TLDR
It is reported that miR-223 limits intestinal inflammation by constraining the nlrp3 inflammasome in mice, revealing a previously unappreciated role in regulating the innate immune response during intestinal inflammation.
Abstract
MicroRNA (miRNA)-mediated RNA interference regulates many immune processes, but how miRNA circuits orchestrate aberrant intestinal inflammation during inflammatory bowel disease (IBD) is poorly defined. Here, we report that miR-223 limits intestinal inflammation by constraining the nlrp3 inflammasome. miR-223 was increased in intestinal biopsies from patients with active IBD and in preclinical models of intestinal inflammation. miR-223(-/y) mice presented with exacerbated myeloid- driven experimental colitis with heightened clinical, histopathological, and cytokine readouts. Mechanistically, enhanced NLRP3 inflammasome expression with elevated IL-1 beta was a predominant feature during the initiation of colitis with miR-223 deficiency. Depletion of CCR2(+) inflammatory monocytes and pharmacologic blockade of IL-1 beta or NLRP3 abrogated this phenotype. Generation of a novel mouse line, with deletion of the miR-223 binding site in the NLRP3 3'untranslated region, phenocopied the characteristics of miR-223(-/y) mice. Finally, nanoparticle-mediated overexpression of miR-223 attenuated experimental colitis, NLRP3 levels, and IL-1 beta release. Collectively, our data reveal a previously unappreciated role for miR-223 in regulating the innate immune response during intestinal inflammation.

read more

Content maybe subject to copyright    Report

Citations
More filters
Journal ArticleDOI

Targeting the NLRP3 inflammasome in inflammatory diseases

TL;DR: Recent advances in the understanding of NLRP3 activation and regulation are reviewed, the evolving landscape ofNLRP3 modulators are highlighted and opportunities for pharmacologically targeting NL RP3 with novel small molecules are discussed.
Journal ArticleDOI

Targeting immune cell circuits and trafficking in inflammatory bowel disease.

TL;DR: In this Review, Neurath delineates the cells, pathways and signals that contribute to the pathology of inflammatory bowel disease and the potential for therapeutic intervention.
Journal ArticleDOI

Interleukin-18: Biological properties and role in disease pathogenesis

TL;DR: There is now ample evidence for a role of IL‐18 in various infectious, metabolic or inflammatory diseases such as influenza virus infection, atheroma, myocardial infarction, chronic obstructive pulmonary disease, or Crohn's disease, however,IL‐18 plays a very specific role in the pathogenesis of hemophagocytic syndromes also termed Macrophage Activation Syndrome.
Journal ArticleDOI

Inflammasome activation and regulation: toward a better understanding of complex mechanisms.

TL;DR: The most recent advances and remaining challenges in understanding the ordered inflammasome assembly and activation upon sensing of diverse stimuli, as well as the tight regulations of these processes are summarized.
Journal ArticleDOI

Anti-inflammatory MicroRNAs and their potential for inflammatory diseases treatment

TL;DR: Recent findings related to significant roles of miRNAs in immune regulation, especially the potential utility of these molecules as novel anti-inflammatory agents to treat inflammatory diseases are discussed.
References
More filters
Journal ArticleDOI

The impact of microRNAs on protein output

TL;DR: The impact of micro RNAs on the proteome indicated that for most interactions microRNAs act as rheostats to make fine-scale adjustments to protein output.
Journal ArticleDOI

The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications

TL;DR: Key issues that have emerged from discussions of the Montreal Working Party are highlighted and the relevance to clinical practice and research activities are highlighted.
Journal ArticleDOI

Inflammatory bowel disease: Etiology and pathogenesis

TL;DR: No single agent or distinct mechanism is the sine qua non motive that explains all aspects of IBD, and several distinguishing factors are likely necessary to result in either CD or UC; this review will attempt to discuss those that currently appear important.
Journal ArticleDOI

Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity

TL;DR: Altered interactions between the gut microbiota and the host, produced by defective NLRP3 and NLRP6 inflammasome sensing, may govern the rate of progression of multiple metabolic syndrome-associated abnormalities, highlighting the central role of the microbiota in the pathogenesis of heretofore seemingly unrelated systemic auto-inflammatory and metabolic disorders.
Related Papers (5)